EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer

Zhang, Xiangyu; Wang, Qi; Qin, Liubing; Fu, Hao; Fang, Yiwei; Bao-Shan, Han; Duan, Yourong

doi:10.3109/10717544.2015.1126769

Cited by 41 publications

(23 citation statements)

References 32 publications

(34 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biodistribution and therapy studies were performed using xenografts of the human non-small cell lung carcinoma cell line (H1299) in mice. The combination treatment suppressed lung cancer growth, and reduced expression of the anti-apoptosis protein, which was confirmed by ex vivo analysis of the tumor tissue ( Yang et al, 2015 ; Yin et al, 2015 ; Zhang et al, 2016 ).…”

Section: Combination Treatments With Plga Npsmentioning

confidence: 58%

PLGA-Based Nanoparticles in Cancer Treatment

et al. 2018

View full text Add to dashboard Cite

Nanomedicines can be used for a variety of cancer therapies including tumor-targeted drug delivery, hyperthermia, and photodynamic therapy. Poly (lactic-co-glycolic acid) (PLGA)-based materials are frequently used in such setups. This review article gives an overview of the properties of previously reported PLGA nanoparticles (NPs), their behavior in biological systems, and their use for cancer therapy. Strategies are emphasized to target PLGA NPs to the tumor site passively and actively. Furthermore, combination therapies are introduced that enhance the accumulation of NPs and, thereby, their therapeutic efficacy. In this context, the huge number of reports on PLGA NPs used as drug delivery systems in cancer treatment highlight the potential of PLGA NPs as drug carriers for cancer therapeutics and encourage further translational research.

show abstract

Section: Combination Treatments With Plga Npsmentioning

confidence: 58%

PLGA-Based Nanoparticles in Cancer Treatment

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Bcl-2) [61, 67, 68], as well as inducing apoptosis by suppressing transcription factor nuclear factor kappa B (NF-κB) [69]. To this end, combination therapy involving a chemotherapeutic agent while inhibiting the aforementioned pathways can effectively treat tumor cells with acquired resistance [32, 62, 63, 67, 70–74]. …”

Section: Rationales and Significance Of Traditional Combination Thmentioning

confidence: 99%

“…The functional side groups composed of PLL cationic polypeptide provide the ability to anchor siRNA through ionic interactions. mPEG-PLGA-b-PLL have been used to co-deliver adriamycin or DOX with Bcl-2 siRNA as a potential treatment strategy for lung cancer [70, 144]. Similarly, other cationic, amphiphilic copolymers have been synthesized to facilitate the loading of siRNA or DNA with other small-molecule drugs.…”

Section: Combination Of Sirna/chemodrugs In a Single Carriermentioning

confidence: 99%

Nanoformulations for combination or cascade anticancer therapy

Miao

Guo

Lin

et al. 2017

Advanced Drug Delivery Reviews

149

View full text Add to dashboard Cite

Nanoparticle drug formulations have been extensively investigated, developed, and in some cases, approved by the Food and Drug Administration (FDA). Synergistic combinations of drugs having distinct tumor-inhibiting mechanisms and non-overlapping toxicity can circumvent the issue of treatment resistance and may be essential for effective anti-cancer therapy. At the same time, co-delivery of a combined regimen by a single nanocarrier presents a challenge due to differences in solubility, molecular weight, functional groups and encapsulation conditions between the two drugs. This review discusses cellular and microenvironment mechanisms behind treatment resistance and nanotechnology-based solutions for effective anti-cancer therapy. Co-loading or cascade delivery of multiple drugs using of polymeric nanoparticles, polymer-drug conjugates and lipid nanoparticles will be discussed along with lipid-coated drug nanoparticles developed by our lab and perspectives on combination therapy.

show abstract

“…The nanoparticle of NDAT can encapsulate a chemotherapeutic drug payload 13 to offer tumor-targeted drug delivery and the prospect of decreased systemic toxicity. The substantial progress made elsewhere in the development of targeted PLGA-based anticancer drug delivery systems has been reviewed by van der Meel et al 14 and Iyer et al 15 Recently described cancer cell-targeting moieties 18 transferrin, 19 chemokine-targeting peptide, 20 modified epidermal growth factor (EGF), 21 and arginine-glycine-aspartic acid (RGD) peptide. 22 In a companion article, 23 we report the use of this delivery system to enhance cisplatin uptake by tumor xenografts and to reduce cisplatin-induced neurotoxicity.…”

Section: Introductionmentioning

confidence: 99%

Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac

Sudha

Bharali

Yalçın

et al. 2017

IJN

View full text Add to dashboard Cite

The tetraiodothyroacetic acid (tetrac) component of nano-diamino-tetrac (NDAT) is chemically bonded via a linker to a poly(lactic- co -glycolic acid) nanoparticle that can encapsulate anticancer drugs. Tetrac targets the plasma membrane of cancer cells at a receptor on the extracellular domain of integrin αvβ3. In this study, we evaluate the efficiency of NDAT delivery of paclitaxel and doxorubicin to, respectively, pancreatic and breast cancer orthotopic nude mouse xenografts. Intra-tumoral drug concentrations were 5-fold (paclitaxel; P <0.001) and 2.3-fold (doxorubicin; P <0.01) higher than with conventional systemic drug administration. Tumor volume reductions reflected enhanced xenograft drug uptake. Cell viability was estimated by bioluminescent signaling in pancreatic tumors and confirmed an increased paclitaxel effect with drug delivery by NDAT. NDAT delivery of chemotherapy increases drug delivery to cancers and increases drug efficacy.

show abstract

EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer

Cited by 41 publications

References 32 publications

PLGA-Based Nanoparticles in Cancer Treatment

PLGA-Based Nanoparticles in Cancer Treatment

Nanoformulations for combination or cascade anticancer therapy

Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac

Contact Info

Product

Resources

About